News

Mucus in Cystic Fibrosis Lungs May Be a Disease Biomarker

Scientists at the Center for Nanomedicine at the Wilmer Eye Institute, part of Johns Hopkins University School of Medicine, may have found a new way to track the stages and the progression of cystic fibrosis (CF) by examining mucus in the lungs of CF patients. If so, mucus under a microscope…

CF Patients Could Be More Resistant to Cholera, Researcher Suggests

A researcher from the Faculty of Medicine, Shiraz University of Medical Sciences, in Iran, has suggested the unconventional idea that people with cystic fibrosis (CF) could be more resilient to cholera and, vice versa, that people who contract cholera could develop resistance to cystic fibrosis. The work, titled “Cystic…

CF Pathogen Defies Treatment Attempt with Novel Drug Combination

A new study revealed that treating P. aeruginosa biofilms with the antibiotic tobramycin together with mannitol — two well-known therapies in treating lung infections in CF — did not reduce overall bacterial load. The study entitled “Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System…

PTC Adds Cystic Fibrosis to Its STRIVE Awards Initiative

The Strategies to Realize Innovation, Vision and Empowerment (STRIVE) Awards, which are granted by PTC Therapeutics, Inc., will now include a focus on cystic fibrosis (CF) advocacy as well. The company recently announced the extension of the STRIVE program and that it will begin offering funding to nonprofit organizations focused on the…

Patent Granted to OrPro Therapeutics’ Lead Candidate Theradux™ for Treatment of Cystic Fibrosis

OrPro Therapeutics, Inc. has announced it has been granted a patent by the US Patent and Trademark Office (USPTO) for its lead candidate Theradux™, covering its unique treatment ability for cystic fibrosis (CF). The company has been developing a treatment pipeline based on thioredoxin, a naturally secreted protein with enzymatic activity known to have…

Vertex, CRISPR to Use Gene Editing in Search for New Cystic Fibrosis Treatments

Vertex Pharmaceuticals, Inc. and CRISPR Therapeutics have announced that they will collaborate on drug research and development using CRISPR’s proprietary gene editing technology CRISPR-Cas9 to discover novel, potential treatments that address the underlying genetic causes of diseases such as cystic fibrosis (CF). The collaboration between Vertex and CRISPR will evaluate the use…